First IL-17A biologic approved for polymyalgia rheumatica - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

First IL-17A biologic approved for polymyalgia rheumatica

  • By

  • Mouj Hijazi

  • November 17, 2026

  • 2 min

Share

  • 1

    The FDA approved secukinumab 150 mg as the first IL-17A inhibitor for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate tapering.

  • 2

    In the 381-participant REPLENISH trial, sustained remission at week 52 occurred in 40.5% of patients receiving secukinumab 150 mg and 20.5% receiving placebo.

  • 3

    Mean adjusted cumulative glucocorticoid dose through week 52 was 1,683.2 mg with secukinumab and 2,093 mg with placebo.

  • 4

    Median time to rescue treatment for a polymyalgia rheumatica flare was 282 days with secukinumab and 157 days with placebo.

  • 5

    The prescribing information warns of serious infections and inflammatory bowel disease and recommends tuberculosis evaluation and age-appropriate vaccinations before treatment.

Original Source(s)

Related Content